

1 **Buforin II-*Escherichia coli*'s DNA interactome: Detailed biophysical** 2 **characterization revealed nanoscale complexes likely formed by DNA** 3 **supercoiling**

4 Daniela Rubio-Olaya¹, Javier Cifuentes¹, Paola Ruiz-Puentes¹, Octavio A. Castañeda², Luis H. Reyes³, Jorge
5 Duitama⁴, Carolina Muñoz¹, and Juan C. Cruz^{1*}

6
7 ¹Department of Biomedical Engineering, Universidad de los Andes, Bogotá, Colombia.

8
9 ²MicroCore Microscopy Center, Vice-Rectoría for Research and Creation, Universidad de los Andes, Bogotá,
10 Colombia.

11
12 ³Grupo de Diseño de Productos y Procesos, Department of Chemical and Food Engineering, Universidad de
13 los Andes, Bogotá, Colombia.

14
15 ⁴Department of Systems and Computing Engineering, Universidad de los Andes, Bogotá, Colombia.

16
17 * Corresponding autor

18
19 E-mail: jc.cruz@uniandes.edu.co (JCC)

20 Keywords: Buforin II; peptide; interactome; nanobioconjugate; *Escherichia coli*.

21

22 **Abstract**

23 Antimicrobial peptides (AMPs) have emerged as exciting alternatives to the alarming increase of
24 multiresistant bacteria due to their high activity against them through mechanisms that are thought to
25 largely avoid resistance in the long term. Buforin II (BUFII) is an antibacterial peptide hypothesized
26 to kill bacteria by crossing their membranes to interact with intracellular molecules and interrupt key
27 processes for survival. In particular, interactions with DNA have been considered crucial for
28 triggering cell death mechanisms. However, such interactions are still unknown, and thus far, no
29 reports are available describing BUFII-DNA complexes. Here, we describe a complete biophysical
30 study of the interaction between BUFII and *Escherichia coli* gDNA via spectrofluorimetric,
31 spectroscopic, and microscopic techniques, complemented with whole-genome sequencing. The *E.*
32 *coli*'s DNA-BUFII interactome was isolated by an *in vitro* pull-down method aided by BUFII-

33 magnetite nanobioconjugates. Our results demonstrated that DNA-BUFII formed round-shape
34 nanoscale complexes by strong electrostatic interactions, likely occurring nonspecifically throughout
35 the entire bacterial genome. Further sequencing of the isolated DNA fragments corroborated this
36 notion and led to hypothesize that BUFII is possibly responsible for inducing DNA's supercoiling.
37 Other evidence for this idea was provided by the significant DNA conformational changes observed
38 upon interaction with BUFII. Even though the evidence found fails to describe the complete action
39 mechanism of BUFII *in vivo*, our findings pave the way to engineer DNA-peptide supramolecular
40 complexes very precisely, which might find application in the field of gene therapy delivery.

41 **Introduction**

42 The development of new treatments for infections caused by multidrug-resistant bacteria has been a
43 challenge for decades due to the remarkable adaptive capabilities of bacteria. The broad spectrum and
44 bactericidal activity of antimicrobial peptides (AMPs) make them promising candidates for
45 treatments against infection (1).

46 Buforin II (BUFII) is a histone-derived peptide found in the stomach of the Asian toad *Bufo*
47 *gargarizans* and the skin of several South American frogs (2). BUFII has 21 amino acids forming
48 helical structures at the N- and C-terminals. The C-terminal region has been thought to contribute to
49 BUFII's antimicrobial activity, giving the peptide a stable amphipathic helical structure for forming
50 supramolecular peptide-lipid complexes. These complexes eventually lead to transient pore formation
51 and membrane penetration, subsequently binding to DNA and RNA, blocking vital functions, and
52 causing cell death (3). This strong interaction tendency has been attributed to BUFII's positively
53 charged arginine and lysine residues (4, 5). Several studies have focused on the ability of BUFII to
54 control infections by introducing small mutations in its structure, and it has been found that it
55 exhibits interaction with bacterial DNA (6-10). However, the knowledge about the type of
56 interactions predominating between BUFII and DNA remains largely unknown, and whether such

57 interactions correspond to specific binding to motifs associated with bacteria's vital processes is
58 undetermined.

59 To improve BUFII's properties in physiological environments, nanobioconjugates of BUFII and
60 magnetite (Mgnt) have been previously developed, where BUFII was immobilized on Mgnt
61 nanoparticles to enhance its stability without significantly altering its membrane-translocating and
62 antibacterial properties. Also, these strategies have enabled drug delivery and medical images
63 associated with the use of magnetic fields that exploit Mgnt's responsiveness to such stimuli (11, 12).
64 These nanobioconjugates are also a promising innovation tool to enable pull-down molecular
65 techniques because of their unique interactions with proteins or peptides *in vitro* (13). Additionally,
66 physicochemical methods previously used in translocating peptides analysis are valuable for
67 understanding the mechanism of action of AMPs, including advanced spectroscopic and microscopic
68 techniques for analyzing the complexes formed by peptide-DNA interactions, determining the
69 underlying structure-activity relationships, and monitoring secondary and tertiary structural changes
70 (14-16).

71 This study analyzes the interaction between the peptide BUFII and genomic DNA of *Escherichia coli*
72 via molecular, spectroscopic, and microscopic techniques complemented with whole-genome
73 sequencing. We showed the ability of BUFII-Mgnt nanobioconjugates to enable pull-down assays to
74 enrich and isolate the interactome of interest. Sequencing data validated the use of BUFII-Mgnt to
75 isolate the interactome and provided insights into the types of interactions with gDNA *ex vivo* that
76 are mainly unspecific. This information was supported by microscopic evidence showing the
77 assembly of nanoscale supramolecular structures as DNA and BUFII complexed together, which can
78 be most likely related to the intricacies of random interactions. We found significant conformational
79 changes in the secondary structure of BUFII upon contact with DNA and demonstrated that
80 electrostatic forces are mainly responsible for such strong BUFII-DNA interactions. Taken together,

81 our results led us to hypothesize that DNA supercoils, through interactions with BUFII, can be
82 further exploited for engineering novel supramolecular complexes for applications in gene delivery.

83

84 **Materials and methods**

85 **Extracting *E. coli* genomic DNA**

86 Genomic DNA from *E. coli* K12 (F- lambda- *ilvG- rfb-50 rph-1*) was extracted by ultrasonication
87 according to the protocol described previously by Zhang et al. (17). Bacteria were cultivated in LB
88 media overnight and centrifuged to discard the medium. Then, cells were washed with TE buffer (10
89 mM tris HCl, 1 mM EDTA, pH 8), and 1.5 mL of sonication buffer (50 mM tris HCl, 10 mM EDTA,
90 100 ng mL⁻¹ RNase, pH 7.5) was added to the pellet along with 1 g of glass beads in 2 mL
91 Eppendorf® tubes. The samples were vortexed for 5 minutes to disrupt cellular membranes and
92 release the genomic content. After centrifugation, the supernatant was transferred to 0.5 mL
93 Eppendorf® tubes and sonicated in cold water into an ultrasonic bath (BRANSONIC 5510R-DTH,
94 Danbury, CT, USA) in 1-minute cycles, six times. Samples were then incubated for 30 minutes at
95 80°C to denature proteins and centrifuged to collect supernatant with DNA fragments of
96 approximately 500 bp in size. To evaluate the purity of the extracted DNA, it was assessed on the
97 optical density ratio of 260 and 280 nm (OD₂₆₀/OD₂₈₀ = 1.8). Additionally, DNA concentration
98 was determined by measuring the absorbance at 260 nm in a spectrophotometer (Denovix Inc, New
99 Castle County, Delaware, USA) at room temperature.

100 **Sample preparation**

101 Buforin II-Magnetite (BUFII-Mgnt) nanobioconjugates were synthesized as previously described
102 (11, 12) to form an aqueous suspension with a 1.6 mg mL⁻¹ final concentration, containing
103 approximately 32 mg mL⁻¹ of BUFII. The complexes were prepared by mixing DNA and

104 nanobioconjugates to obtain different ratios between anionic charges of the *E. coli* K12 DNA
105 fragments and cationic charges of the peptide (N⁺:P⁻ ratio). Complexes prepared with the
106 nanobioconjugates and DNA were incubated at 4 °C for 1 hour under constant agitation.
107 Additionally, complexes of BUFII and DNA were prepared by adding a binding buffer (5% glycerol,
108 10 mM tris HCl, 1 mM EDTA, 1 mM DTT) to the mixture, followed by incubation at 4 °C for 30
109 minutes under agitation.

110 **Agarose gel electrophoresis**

111 Agarose gel electrophoresis was carried out to verify DNA extraction and BUFII interaction with
112 DNA. Samples were solubilized in 6X loading buffer (New England Biolabs Inc., Ipswich, USA) and
113 then separated by migration on a 1% agarose gel dissolved in TBE buffer (10.8 g L⁻¹ tris, 0.5M
114 EDTA, 5.5 g L⁻¹ boric acid, pH 8) in the presence of HydraGreen (3 mL, ACTGene, USA) as the
115 intercalating agent. Electrophoresis was carried out for 1 hour at 90 V using an electrophoresis
116 system (mini-DNA SUB CELL, Bio-Rad, Mississauga, Canada). The DNA fragments were
117 visualized in a Gel Doc XR+ Gel Documentation System (Bio-Rad, Mississauga, Canada) and
118 photographed.

119 **Pull-down and next-generation sequencing (NGS)**

120 To obtain the *E. coli* K12 gDNA fragments that interacted with BUFII, complexes with the
121 nanobioconjugates were prepared as described above. As shown in Fig 1A, particles were
122 precipitated with a magnet, and the supernatant was removed. The complexes were washed with
123 sterile distilled deionized water twice to remove non-interacting fragments. BUFII/DNA complexes
124 were then eluted by adding 100 µL of elution buffer (1% SDS, 0.1 M NaHCO₃, pH 8), vortexed for
125 10 minutes, and spun down at 13,000 RPM for 5 minutes. A negative control assay was performed
126 using Mgnt nanoparticles without BUFII instead of nanobioconjugates to dismiss unspecific

127 interactions. The supernatant with 100-500 bp DNA fragments was purified with Monarch PCR &
128 DNA Cleanup Kit (New England Biolabs Inc., Ipswich, USA) and stored at -80 °C until further use.
129 Whole-genome sequencing was performed on the Illumina NovaSeq platform using Truseq ChIP-seq
130 library and protocols (Illumina, San Diego, CA, USA) with a minimum Phred quality score of 30. A
131 total production of 2 Gbp on raw data for each sample was obtained from the sequencing process,
132 which corresponds to a genome-wide average depth of 400X. Two samples were sequenced, a
133 sample obtained from the previously described interaction assay and a negative control performed as
134 described previously, but in the absence of BUFII to detect the nonspecific interactions between
135 DNA and bare Mgnt.

136 **Fig 1. BUFII interactome pull-down description and validation.** (a) Schematic of BUFII-DNA
137 pull-down assay using magnetic properties of magnetite (Mgnt) nanoparticles in BUFII-Mgnt
138 nanoconjugates to isolate interacting fragments of *E. coli* DNA. Created with BioRender.com (b)
139 Agarose gel for pull-down verification. BUFII:DNA1:4/1:1, isolated fragments from interaction with
140 Mgnt-BUFII nanobioconjugates with DNA fragments. (-) Control, isolated fragments from
141 interaction with magnetite nanoparticles. (+) Control, genomic DNA fragments.

142

143 **Analysis of sequenced data**

144 The genome assembly of the *E. coli K12* strain with accession ID AP009048.1 was downloaded from
145 the NCBI Nucleotide database and used as a reference for the analysis. Raw reads were mapped to
146 the genome using bwa mem v. 0.7.12 with default parameters (18). Windows of 100 bp showing
147 significant differences in reading depth between the treated and the control sample were identified
148 running the ReadDepthComparator command of NGSEP v4.1.0 (19). Windows with a p-value below
149 10^{-6} and log fold-change above 4 were selected. Windows separated by less than 1 kbp were merged
150 to identify the peaks of differential read depth. Bedtools v2.30.0 was used to generate FASTA files

151 from the coordinates in pair bases corresponding to each peak. Results were visualized in the
152 Integrative Genomics Viewer. Sequences from the FASTA files were searched using the BLAST tool
153 from NCBI (20) to identify encoding genes in bacteria and provide insights into the possible
154 biological functions altered by the interaction with BUFII.

155 **Fluorescence measurement**

156 The fluorescence spectra of *E. coli K12* genomic DNA in the presence and absence of BUFII were
157 measured using a FluoroMax4 spectrofluorimeter from HORIBA Scientific at room temperature as
158 described previously (21). Data were collected using the FluorEssence® software. The reference
159 excitation monochromator and detector were previously verified and calibrated with water and
160 rhodamine B to avoid temporal fluctuations in the source during excitation scans. The excitation
161 wavelength was set at 535 nm, and emission spectra were measured between 550 and 750 nm for
162 increasing BUFII concentrations (0, 9, 18, 36 $\mu\text{g mL}^{-1}$) to a DNA fixed concentration (25 $\mu\text{g mL}^{-1}$).
163 The measurements were conducted for both BUFII-Mgnt/DNA complexes and BUFII/DNA
164 complexes.

165 **Competitive binding of BUFII and SybrGreen (SG) with bacterial DNA**

166 Additional fluorescence measurements were carried out to analyze competitive binding. Assays were
167 carried out in denatured water containing a fixed concentration of SybrGreen (3 $\mu\text{g mL}^{-1}$)-DNA (25
168 $\mu\text{g mL}^{-1}$) with varying concentrations of BUFII (0, 9, 18, and 32 $\mu\text{g mL}^{-1}$). The SG-DNA solution
169 was incubated at room temperature for 10 min to allow the mixture to reach equilibrium. Then,
170 BUFII-Mgnt/BUFII were added to the SG-DNA solution, and the fluorescence spectra were
171 recorded between 500 and 700 nm for each test solution with an excitation at 490 nm.
172 The competitive binding of SG against BUFII and bacterial DNA was also probed via fluorescence
173 measurements. The assays were carried out in denatured water in the presence of a fixed
174 concentration of BUFII (18 $\mu\text{g mL}^{-1}$)-DNA (25 $\mu\text{g mL}^{-1}$) and varying the concentrations of SG,

175 making serial dilutions (1:2) of the previous concentration (0, 0.75, 1.5 and 3 $\mu\text{g mL}^{-1}$). The
176 BUFII/BUFII-Mgnt-DNA solution was incubated at room temperature for 10 min to reach
177 equilibrium. Then the solution containing SG was added to the BUFII/BUFII-Mgnt-DNA solution.
178 The solutions were excited at 490 nm, and the emission spectra were recorded from 500 to 700 nm.

179 **Fourier-Transform Infrared Spectroscopy (FTIR)**

180 Samples were prepared as described previously. BUFII-Mgnt nanobioconjugates were precipitated to
181 discard the supernatant and dilute the complexes in deuterated water. Samples were examined on a
182 Bruker Alpha II FTIR Eco-ATR instrument (Bruker Optik GmbH, Ettlingen, Germany). The peptide
183 concentration was kept at 32 $\mu\text{g mL}^{-1}$, and the corresponding amount of *E. coli K12* DNA fragments
184 was added to match the desired molar ratios. Droplets from solutions were placed on top of the
185 instrument's germanium crystal, and data were collected between 4000-600 cm^{-1} with a spectral
186 resolution of 2 cm^{-1} . After measurements, FTIR curves were smoothed out for noise suppression by
187 replacing the intensity value of each data point with the value obtained by averaging the intensities of
188 three points. The measurements were performed for both BUFII-Mgnt/DNA complexes and
189 BUFII/DNA complexes.

190 To analyze changes in the secondary structure of BUFII upon complexing with DNA, the Amide I
191 and II (1800 cm^{-1} - 1500 cm^{-1}) spectra were deconvoluted aided by the second derivative of the
192 spectra as described previously by Kong and Shaoning (22).

193 **Transmission Electron Microscopy (TEM)**

194 TEM imaging (FEI, Tecnai F20 Super Twin TMP, Hillsboro, OR, USA) was carried out for
195 complexes with both immobilized and free BUFII and *E. Coli K12* DNA fragments (1:1). The
196 samples were fixed onto lacey Carbon grids by depositing drops of the main solution (0.1 mg mL^{-1})
197 on the top and letting them rest for 5 minutes. Next, uranyl acetate staining was performed by adding

198 5 μ L of 2% uranyl acetate solution and leaving the sample to rest for 5 minutes at room temperature.
199 The microscope was operated at a 200 keV acceleration voltage to visualize the samples.

200 **Atomic Force Microscopy (AFM)**

201 Topography AFM images were obtained using an MFP3D-BIO AFM (Asylum Research, Santa
202 Barbara, CA, USA) instrument. As described by Pillers et al., samples were prepared to immobilize
203 complexes with both free and immobilized in Mgnt BUFII and *E. coli* K12 DNA fragments (1:1) on
204 silicon substrates. Silicon surface chips were previously cleaned using RCA1 (28 % ammonium
205 hydroxide, 30% hydrogen peroxide, DI water) and RCA2 (14% hydrochloric acid, 30% hydrogen
206 peroxide, DI water) solutions (23). Silicon chips were functionalized with a 2% (3-aminopropyl)
207 triethoxysilane (APTES, 98%, Sigma-Aldrich, St. Louis, MO, USA) solution to attach complexes to
208 the surface by interactions with free amine groups. The main sample solution was then mixed, and 4
209 μ L were deposited on the silicon substrate. Samples were left to rest for about 10 minutes and then
210 rinsed with 100 μ L of sterile 18 M Ω x cm water and dried with N₂ for 1 min. The samples were
211 stored in a clean container until further experiments to avoid possible artifacts during imaging. All
212 measurements were conducted with an AC240TS cantilever (Oxford Instruments, Asylum Research,
213 Santa Barbara, CA, USA) using the tapping mode set at a 70% free amplitude setpoint. The images
214 were obtained using different scan sizes in a range from 1.5 μ m x 1.5 μ m up to 5 μ m x 5 μ m at a
215 resolution of 1024 by 1024 pixels and with a scan rate of 1 Hz.

216 **Results and discussion**

217 **Nanobioconjugates allowed obtaining the BUFII interactome with DNA**

218 Pull-down experiments aided by BUFII-Mgnt nanobioconjugates allowed the successful isolation of
219 *E. coli* K12 DNA fragments that interacted with immobilized BUFII, as described in Fig 1A. The
220 interactome showed in the electrophoresis gel (Fig 1B) corresponds to assays performed with DNA

221 fragments ranging from 200 bp to 1 kbp. However, it was possible to isolate only those between 100
222 and 500 bp. Also, it was found that Mgnt shows some level of interaction with DNA, which is most
223 likely due to electrostatic interactions with charged functional groups present on the surface of Mgnt.
224 We performed direct sequencing of the DNA present in the experiment, as well as the DNA in the
225 control experiment. As shown in Fig 2A, data from sequencing were successfully mapped to the K12
226 reference genome and visualized to determine whether the proposed method is sufficiently robust to
227 isolate the interacting *E. coli K12* DNA fragments accurately. The panel shows an example of the
228 depth distribution around the *bcsA* gene. Although the depth is around the expected average of 400X,
229 important differences are observed between samples, indicating that BUFII interaction with DNA is
230 distinguishable from that between DNA and bare Mgnt. Additionally, regions of significantly higher
231 read depth were identified for the library of the BUFII-containing sample, which in comparison with
232 the control, suggest the presence of specific interactions.

233 **Fig 2. Sequencing data from BUFII interactome visualization.** Data from interactomes was
234 mapped and visualized to identify motifs associated with the antimicrobial activity of BUFII using
235 interaction between *E. coli K12* DNA and Mgnt as a control. (a) Visualization of a fragment of
236 mapped reads showing differences in the enrichment patterns between samples. (b) Sample from
237 interaction with BUFII showed important enrichment in the genome coordinates associated with LacI
238 repressor gene compared to Mgnt sample.

239

240 **BUFII-DNA interaction is mainly unspecific but appears to have an** 241 **affinity towards some DNA sequences**

242 In general, the BUFII containing sample showed regions over the whole genome with significantly
243 high depth (above 1000X). Conversely, no coverage was obtained in some other regions, an
244 observation that will be studied further in our future contributions. Fig 2B shows the most interest

245 difference in read depth between samples. The BUFII containing sample has a zone of enrichment
246 that reaches approximately 130000X, indicating a particular affinity of the peptide towards the
247 indicated 400 bp region, which was not observed in the Mgnt control.

248 We then proceeded to search for peaks indicating a higher affinity of the peptide for specific regions
249 of the genome. The most relevant ones correspond to the same zone of higher enrichment between
250 365401 and 365800 bp. The sequences in FASTA format were recovered from the peak positions to
251 evaluate their biological function and whether it was related to the antimicrobial activity of BUFII.

252 The analysis of the sequences shows that this region encodes for the Lac operon and specifically for
253 the LacI repressor and the β -galactosidase enzyme. The function of this region is to switch the
254 metabolic pathway from glucose to lactose when the bacterium is in a medium with low glucose
255 content but rich in lactose or any of its derivatives (24).

256 Additionally, the MEME suite software version 5.4.1. (25) was used to try to identify motifs enriched
257 at the regions with differential read depth. Unfortunately, the number of regions with significant
258 differences in read depth was insufficient to predict with enough statistical significance specific
259 interactions with DNA motifs. However, this initial interaction experiment suggests that despite the
260 largely unspecific interaction between BUFII and phosphate groups in the DNA backbone chain as
261 has been described previously (7, 9), the peptide showed a surprisingly greater affinity towards some
262 specific DNA sequences. Our data is not conclusive to explain this result. Hence, we are planning to
263 conduct further in silico and experimental studies that involve MD simulations and calorimetric
264 measurements of the interacting complexes.

265 To validate the data related to the enriched zone corresponding to LacI repressor in the *E. coli* K12
266 Lac Operon, an assay described in the supplementary material for inducing GFP expression with the
267 BUFII-Mgnt nanobioconjugates was performed. The obtained results demonstrated that the BUFII-
268 Mgnt inhibited the LacI repressor, leading to GFP expression (S1 Fig). Despite confirming the
269 particular affinity of BUFII towards this sequence, the experiment failed to explain the potent

270 antimicrobial activity of BUFII because there is no evidence of metabolic alterations that
271 compromise vital bacterial functions. Sequencing data and the validation experiment let us elucidate
272 that BUFII might have an affinity for some DNA motifs; however, the underlying interaction is
273 mainly unspecific.

274 **BUFII-DNA interaction is mainly mediated by electrostatic interactions**

275 **BUFII-DNA interaction**

276 Fluorometric assays performed with complexes containing BUFII and gDNA fragments isolated
277 from *E. coli K12* (0–32 $\mu\text{g mL}^{-1}$) provided additional insights into the possible underlying
278 mechanisms for the observed interactions.

279 As shown in Fig 3A, in the absence of BUFII, the DNA of *E. coli K12* emitted a characteristic
280 fluorescence profile in water at room temperature, with a peak close to 585 nm after excitation at 535
281 nm. Upon adding BUFII-Mgnt into the DNA solution, the fluorescence intensity decreased
282 dramatically, most probably due to the ability of Mgnt nanoparticles to absorb the fluorescence
283 emitted by the BUFII-DNA complexes or by the steric hindrance caused by the Mgnt nanoparticles
284 that prevent sufficient DNA and BUFII encounters for a sustained interaction that can be monitored
285 spectrofluorimetrically.

286 **Fig 3. BUFII-DNA complex spectrofluorometric assays.** (a) Fluorescence spectra of DNA fragments
287 in the presence of increasing amounts of BUFII. A fixed concentration of DNA was mixed with
288 increasing amounts of BUFII/Mgnt-BUFII. Samples were excited at 535nm. (b) Fluorescence spectra
289 of DNA fragments and BUFII in the presence of SybrGreen (SB), a fixed concentration of DNA and
290 SB was mixed with increasing amounts of BUFII/Mgnt-BUFII. (c) Fixed concentration of DNA and
291 BUFII/Mgnt-BUFII was mixed with increasing amounts of SB. Samples were excited at 490 nm.

292

293 The behavior of fluorescence signals changed as the concentrations of BUFII increased. This might
294 be primarily due to changes in the DNA backbone structure, similar to previously reported DNA
295 clustering that reduces fluorescence intensity and decreases the collisional frequency of solvent
296 molecules with DNA (26). Spectrofluorimetric techniques have been successfully used to detect
297 specific DNA–protein binding because they allow direct measurement of binding in solution.
298 Changes in the fluorescence emission spectrum of a protein upon binding to DNA can often be used
299 to determine the stoichiometry of binding and to decipher the types of molecular interactions (27-29).
300 In this case, data indicate that BUFII could interact with the backbone DNA or locate deep into the
301 DNA hydrophobic regions, evidenced by fluorescence intensity changes because of the difference in
302 the amount of light absorbed at excitation and emission wavelengths. The results point toward an
303 incomplete inhibition of the DNA fluorescence spectra.

304 **Competitive binding of BUFII and SG with bacterial DNA**

305 To further decipher the mechanistic details of the interactions between BUFII with DNA, a
306 competitive binding experiment was carried out using SybrGreen (SG) as a double-stranded DNA
307 (dsDNA) intercalating agent ($\lambda_{\text{ex}} = 490 \text{ nm}$ and $\lambda_{\text{em}} = 500\text{--}700 \text{ nm}$). This method was used to assess
308 the ability of the peptide to prevent the intercalation of SG within DNA strands. In general, when
309 small molecules like SG bind to dsDNA, interaction cause changes in the fluorescence spectra
310 compared to what is observed for solutions in the absence of this ligand. However, fluorescence
311 quenching will be observed when a second ligand competes for the DNA-binding sites (30).
312 As shown in Fig 3B, the addition of BUFII to dsDNA pretreated with SG caused a noticeable
313 fluorescence quenching, indicating that BUFII competed with SG in binding to DNA. This
314 observation suggested that BUFII replaced some SG molecules that interacted with the DNA base
315 pairs and released them into the aqueous solution. Consequently, a decrease in the emission was
316 observed (31). However, fluorescence spectra for each sample show that the reduction in

317 fluorescence is not directly proportional to the concentration of BUFII/BUFII-Mgnt. At a
318 concentration of 18 mg mL⁻¹, the fluorescence signal was reduced, suggesting that the interaction
319 between the molecules is most likely mediated by electrostatic forces, which, after reaching an
320 equilibrium (cation:anion), might favor the ability of the peptide to intercalate between adjacent base
321 pairs and replace the SB molecules (32).
322 Further support for the proposed mechanism of BUFII binding to DNA via intercalation was given
323 through a competitive binding assay of SG with bacterial dsDNA against BUFII (Fig 3C). With the
324 addition of SG, the characteristic fluorescence band of the BUFII–DNA complex with a maximum at
325 about 535 nm (excited at 490 nm) rose gradually, indicating that some of the SG molecules
326 intercalated into the DNA base pairs instead of BUFII. SG–DNA replaced BUFII–DNA gradually,
327 showing that, in this case, an increase in fluorescence intensity was proportional to SG concentration.
328 This supports previous information on the specific interaction between peptides and bacterial DNA,
329 pointing towards electrostatic interactions mediated by the existing charge differences.
330 To dismiss the effect of Mgnt nanoparticles in the interaction between DNA and BUFII, negative
331 controls for all Mgnt-BUFII nanobioconjugates concentrations were performed by adding bare Mgnt
332 (S2 Fig). The obtained data suggest an interaction between Mgnt nanoparticles and DNA, as
333 evidenced in the pull-down assay; however, the observed changes in the fluorescence spectra of DNA
334 are negligible in the presence of Mgnt. Additionally, information obtained for BUFII-Mgnt
335 nanobioconjugates was consistent with that of BUFII alone, confirming that even after
336 immobilization on nanoparticles, BUFII can still interact with bacterial dsDNA very strongly.

337 **Changes in BUFII-DNA complexes' secondary structure**

338 FTIR assays were carried out to identify changes in the secondary structure of both DNA and BUFII
339 when forming complexes and to gain insights into the chemical groups playing a role in
340 complexation. The vibrational spectra of the samples showed that specific functional groups appear

341 responsible for the association between BUFII and DNA. Also, they reveal important information on
342 the impact of charge changes in complexation for each ratio (+:-) studied.

343 Experiments were focused on two major regions of the infrared spectrum, the sugar–phosphate
344 region of DNA and the amide I and amide II bands of the peptide. The first range encompasses
345 wavenumbers between 950 and 1200 cm^{-1} , which carries information on chemical bonds associated
346 with the DNA phosphate and ribose groups. In contrast, the second region locates between 1500 and
347 1800 cm^{-1} and encompasses vibrations related to NH moieties on peptide backbones. Also, vibrations
348 associated with DNA guanine groups can be found between 1700 and 1800 cm^{-1} .

349 **Sugar-phosphate region**

350 Data from the sugar–phosphate region shown in Figs 4A and 4C reveals the effect of complexation
351 on the DNA backbone. There are vibrations related to involved functional groups as a function of the
352 evaluated charge ratios. Particularly, bands associated with stretching of C–O bonds of deoxyribose
353 and stretching of $-\text{PO}_2^-$ groups located at 1033 and 1084 cm^{-1} (33). Conformational changes in
354 DNA's backbone are evidenced by peak shifts between 1084 and 1048 cm^{-1} , indicative of
355 interactions between DNA phosphate groups and BUFII. Changes in the 1084 cm^{-1} peak are related
356 to the reorganization of groups adjacent to phosphates, indicating considerable conformational
357 changes in the DNA strands (34).

358 **Fig 4. Spectroscopy assays from solutions containing BUFII/Mgnt-BUFII and genomic *E. coli***
359 ***K12* DNA at different molar ratios.** (a, c) FTIR data collected across spectral range corresponding to
360 the sugar-phosphate region [950-1200 cm^{-1}]. (b, d) FTIR data collected across spectral range
361 corresponding to the peptide amide I band [1800-1750 cm^{-1}]. (e, f, g) Spectra of the Amide I and
362 carbonyl stretching region were deconvolved into component sub-bands to analyze secondary
363 structural changes of BUFII aided by the second derivative of FTIR spectra for BUFII (e), BUFII/DNA
364 1:1 complex (f) and BUFII/DNA 1:4 complex (g).

365

366 When comparing the complexes' bands with free DNA spectra, the shifting in the peak at 1048 cm^{-1}
367 seems related to interactions occurring at charge ratios closer to neutrality. This supports the findings
368 based on fluorescence for the peptide-DNA interaction mediated by electrostatic forces discussed
369 above. Taken together, our data suggest that it is very likely that BUFII/DNA complex formation
370 proceeds by polyelectrolyte brush states that result in unique 3D topologies (possibly due to different
371 BUFII interacting conformers, see below), as has been reported previously (35).

372 **Amide I and II region**

373 Figs 4B and 4D show infrared spectra across the amide I region. In this case, solutions containing
374 complexes closer to the neutrality exhibit spectra with peaks with increased intensity and sharpness,
375 whereas those with the prevalence of cationic charges show a significant intensity reduction (36).
376 These changes may also suggest the appearance of new peptide conformers upon complexation with
377 DNA. Differences in the characteristic amide band between 1700 and 1600 cm^{-1} are related to beta-
378 sheet conformations and disordered structures associated with random coil and clustered
379 conformations (37).

380 **Deconvolution of Amide I and carbonyl stretching region**

381 To identify the secondary structural changes in the formed BUFII/DNA complexes, we analyzed the
382 amide I and carbonyl stretching region (1500 - 1800 cm^{-1}), deconvolving each spectrum with the aid of
383 the second derivative. Secondary structure was estimated under the principle that absorbance reflects
384 the backbone conformation of proteins maintained by hydrogen bonding. Consequently, the
385 deconvolved sub-bands in the amide I region can be correlated with α -helices, β -sheets, turns, and
386 random coils (22).

387 BUFII spectra, when interacting with DNA, are shown in Fig 4E. The Amide I band was
388 deconvolved into three sub-bands: the first one peaking at 1650 cm^{-1} and related to α -helices, the

389 second one at 1606 cm^{-1} associated with disordered structures and aggregated beta-sheets that may
390 arise when the peptides are dissolved in aqueous media. In this regard, it has been reported that
391 BUFII tends to form aggregates and disordered structures different from its mainly known helical
392 conformation (38). Finally, a third small band at 1675 cm^{-1} may be related to the disordered coil of
393 BUFII. The α -helical conformations were confirmed by the Amide II peak at 1510 cm^{-1} , while the
394 disordered ones and beta-sheets were confirmed by a peak at 1558 cm^{-1} in the Amide II band.
395 When an equimolar gDNA concentration is added to the BUFII solution, drastic changes are
396 observed in the deconvolution profile in Fig 4F, with the presence of four sub-bands showing a shift
397 in the α -helices predominance towards aggregated structures, as evidenced by a percentage increase
398 in the turns in the peaks at 1695 and 1670 cm^{-1} . The changes indicate that the conformational changes
399 of BUFII occur to improve interaction with DNA. This has been confirmed by published data that
400 suggest that binding between the carbonyl groups of peptides and the phosphate groups of DNA are
401 favored in the presence of β -sheets (39).
402 Fig 4G shows the FTIR deconvolution upon adding a fourfold molar concentration of DNA to the
403 BUFII solution. A change in the spectrum indicates a predominance of aggregated β -sheets (1623
404 cm^{-1} peak). Also, a decrease in intensity and shift from 1552 to 1572 cm^{-1} within the amide II band
405 strongly suggests changes in the N-H stretching mode of adenine, which can be correlated to specific
406 interactions with DNA motifs and structural alterations along the backbone (40). This validates
407 further the information obtained by the fluorescence studies discussed above, indicating that
408 equimolar ratios favor charge-mediated interactions.

409 **BUFII-DNA complexes are nanoscale supramolecular structures**

410 Transmission electron microscopy (TEM) imaging was conducted to provide insights into the
411 complex formation between free and immobilized BUFII and *E. coli K12* DNA fragments. Images
412 obtained allowed us to elucidate the morphology and size of each complex, and to elaborate more

413 compelling arguments about the identified secondary structural changes presented above. According
414 to the molar equivalence between positive and negative charges, samples were prepared from
415 solutions containing peptides at a concentration of 0.1 mg mL^{-1} . Micrographs shown in Fig 5A
416 confirm complexation between the peptide and DNA. They reveal the formation of discrete
417 nanostructures with sizes ranging from a few nanometers up to hundreds of nanometers. These
418 structures suggest that molecules interact to form rounded structures, most likely due to the presence
419 of BUFII interacting conformers capable of packaging DNA strands very tightly through electrostatic
420 interactions with the phosphate groups (i.e., the phosphodioxy group), as demonstrated by the
421 collected spectroscopic data (see above). Additionally, these interactions seem to lead to regions
422 where DNA strands appear highly supercoiled; however, the underlying mechanisms are yet to be
423 described.

424 **Fig 5. TEM and AFM micrographs from complexes formed between free and immobilized**
425 **BUFII and DNA fragments at a molar charge ratio of 1:1. Presence of globular complexes of**
426 **BUFII and DNA strands throughout the samples.** (a) TEM micrograph for fixed BUFII/DNA
427 complexes revealing round-shape structures. Darker spots correspond to BUFII aggregates, while
428 DNA strands are visible as supercoiled white patches along the formed complexes. (b) TEM
429 micrographs of complexes formed between Mgnt-BUFII nanobioconjugates and DNA. Even though
430 no apparent structures are observable, DNA appears to coat the nanobioconjugate surfaces. (c) AFM
431 micrograph and 3D reconstruction for BUFII/DNA complexes, round-shape structures are formed
432 upon the interaction between molecules. (d) Shows AFM image of DNA molecule in a disordered
433 structure by immobilization on a polished silicon wafer surface. (e) AFM image of agglomerates
434 formed after Mgnt-BUFII nanobioconjugates and DNA interaction.

435

436 For a closer inspection of the complexes, we focused on one of the supramolecular structures formed.
437 Fig 5A shows that most likely, BUFII locates the core of the structure, serving as a scaffold to

438 support the DNA strands supercoiling around the aggregated peptides to give rise to rounded
439 structures. This confirms the findings of the FTIR assays corresponding to the appearance of
440 disordered BUFII structures and the changes in the DNA backbone associated with twisting the outer
441 groups of the strands and, in turn, altering the planarity of the DNA molecule.

442 For BUFII-Mgnt nanobioconjugates, micrographs (Fig 5B) showed the nanoparticles coated by the
443 DNA, confirming that immobilization does not affect the interacting ability of the peptide. However,
444 it was impossible to fully identify the presence of different supramolecular complexes mainly
445 because of the differences in the size of the analyzed structures and the nanobioconjugates.

446 **Imaging of BUFII-DNA confirmed strong interactions and unique** 447 **supramolecular organization**

448 To further understand the topology of the complexes, we also conducted imaging by AFM. Figs 5C
449 and 5D show evident topological differences between the typical structure of the DNA and the
450 formed BUFII-DNA complexes. Free DNA strands appear elongated and disordered, probably due to
451 the immobilization protocol. After adding the peptide and immobilizing it on the silicon wafer
452 surface at the 1:1 molar ratio, imaged complexes showed structures similar to those observed by
453 TEM. Fig 5C revealed rounded structures of various sizes with DNA strands surrounding BUFII and
454 forming a more extensive interconnected system.

455 The formed complexes show DNA strands with similar thicknesses, indicating that the peptide
456 remains at the core while the DNA supercoils form a shell. The interaction between Mgnt-BUFII
457 nanobioconjugates and DNA shown in Fig 5E confirms the DNA aggregation/condensation over the
458 nanobioconjugates, as evidenced previously by the TEM imaging. However, no large structures were
459 observable in the presence of the nanobioconjugates, suggesting that immobilization of the peptide
460 might alter BUFII-DNA interactions, which is likely why the antimicrobial activity of BUFII reduces
461 upon immobilization (12, 41). To our knowledge, no reports are available describing this possible

462 DNA-peptide interaction mechanism, which suggests that this could be a new approach to studying
463 the action mechanism of AMPs with translocating properties like BUFII.

464 **BUFII-DNA complexation: Structure and types of interactions.**

465 The results presented above reveal that the interaction between BUFII and DNA results in the
466 formation of nanocomplexes of different shapes and sizes. The collected data provided several
467 insights into the organization of molecules upon interaction and allowed us to find a rationale for the
468 identified secondary structural changes. Moreover, we are putting forward a complete description of
469 the assembly process for the BUFII-DNA complexes. In addition, we found compelling evidence for
470 the significant role that the charges of involved molecules might play during this process. Finally, our
471 findings point to a multistage assembly process occurring at different scales as larger structures
472 appear composed of smaller interacting subunits.

473 Our proposal for the mechanism of complex assembly is schematically shown in Fig 6. According to
474 this model, complexation is mainly triggered by electrostatic attraction between the negative charges
475 of DNA phosphate groups and the cationic groups of peptide chains (Fig 6A). The initial
476 supramolecular association is represented by the conformational changes of nucleic acid duplexes
477 caused by interacting conformers of BUFII. The role of electrostatic forces as a significant self-
478 assembling driving force is supported by spectrofluorimetric information in competitive DNA
479 binding assays that suggests that BUFII could replace other strongly bound molecules. However, this
480 type of interaction is weaker than a covalent bond, and therefore it is likely reversible (Fig 6B).

481 **Fig 6. Schematic representation of the proposed interactions to form BUFII/DNA complexes.**

482 **Self-assembly is most likely mediated by electrostatic forces causing conformational changes in**

483 ***E. coli* DNA backbone and random agglomerated structures for BUFII.** (a) Ratios that allow

484 equimolar charges between peptide and DNA when forming the complexes result in stronger

485 interactions. (b) Electrostatic forces appear to mediate the interactions, and secondary structural

486 conformation changes facilitate BUFII binding to DNA. (c) Interaction between molecules results in
487 a large complex composed of round-shape structures containing BUFII agglomerates. Strands tend to
488 form different structures because of BUFII's supercoiling induction.

489

490 The formation of rounded structures composed of DNA strands surrounding BUFII aggregates is
491 illustrated in Fig 6C, along with AFM images showing large, microscopic structures in the range of
492 4-6 μm . Aggregates correspond to subunits found making part of larger DNA strands resulting from
493 BUFII's interacting conformers. The observed structures with unique topological features are
494 hypothesized to be formed because of the supercoiling of the DNA induced by BUFII. In this regard,
495 when DNA binds to proteins by electrostatic interactions that can constrain supercoils, negative and
496 positive interactions lead to increased rotational dynamics and the formation of compact complexes
497 made of the loop, thereby causing changes in transcriptional machinery (42).

498 Because of the presence of DNA strands in the periphery of complexes, we propose that a
499 rearrangement of their backbone structure accompanies complex formation. This reorganization is
500 driven mainly by interactions related to the amphiphilicity of the peptide molecules. Indeed, because
501 BUFII contains a significant number of nonpolar groups, the resulting hydrophobic effect is likely
502 responsible for helping the peptide locate at the cores of the supramolecular assemblies. In contrast,
503 the high hydrophilicity of double-helix phosphates would compel DNA toward the interfaces with
504 water (43).

505 **Conclusion**

506 Previous studies of the functional mechanisms of BUFII have focused mainly on the peptide–
507 membrane interaction, which represents the initial step of the bactericidal process. However, little is
508 known about the BUFII–intracellular targets interaction and specifically with DNA, as it has been
509 considered the molecular target responsible for compromising bacterial survival.

510 Here, we reported on a novel technique to perform pull-down assays to study the BUFII-DNA
511 interaction that takes advantage of the magnetic properties of magnetite nanoparticles, which were
512 employed as supports for peptide immobilization. Characterization techniques showed that DNA-
513 BUFII strong interaction leads to the formation of spherical supramolecular complexes with
514 nanoscale dimensions. Based on the measurements of such complexes, DNA molecules appear
515 supercoiled surrounding BUFII. Although sequencing data analysis of enriched fractions failed to
516 provide statistically significant information regarding interaction with specific motifs that could
517 explain the antimicrobial activity of BUFII, the enrichment of the gene for LacI binding repressor
518 and the experimental microscopy and FTIR results provided insights into possible sequence-mediated
519 interactions that will be explored in detail in our future contributions. Notably, the absence of reads
520 in specific regions of the genome offers further evidence for the notion of supercoiling induced by
521 BUFII, as such DNA structures have been reported to be difficult to sequence. Future studies will
522 also focus on exploring the strength of peptide-DNA interactions with the aid of molecular dynamics
523 simulations and calorimetric techniques. Our studies also provide an avenue into the rational design
524 of peptide-DNA supramolecular structures with unique topological features, which might be applied
525 in the engineering of novel gene delivery vehicles.

526

527 **Supporting information**

528

529 **S1 Fig. Buforin II operon Lac induction validation and spectrofluorometric assay.** (a) Assay

530 principle for the use of BUFII-Mgnt nanobioconjugates for the induction of GFP as a consequence of
531 the interaction between the peptide and Operon Lac genes. (b) Visualization of GFP expression in
532 bacteria under UV light for the samples induced with different non-lethal concentrations of BUFII-
533 Mgnt. (c) Fluorescence measurements to quantify relative GFP expression in bacteria. Experiments
534 were conducted in triplicate to dismiss false positives.

535 **S2 Fig. Mgnt-DNA interaction control spectrofluorometric assays.** (a) Fluorescence spectra of
536 DNA fragments in the presence of increasing amounts of Mgnt. A fixed concentration of DNA was
537 mixed with increasing amounts of Mgnt. Samples were excited at 535nm. (b) Fluorescence spectra of
538 DNA fragments and Mgnt in the presence of SybrGreen (SB). A fixed concentration of DNA and SB
539 was mixed with increasing amounts of Mgnt. (c) Fixed concentration of DNA and Mgnt was mixed
540 with increasing amounts of SB. Samples were excited at 490 nm.

541 **References**

- 542 1. Andersson DI, Hughes D, Kubicek-Sutherland JZ. Mechanisms and consequences of bacterial
543 resistance to antimicrobial peptides. *Drug Resistance Updates*. 2016;26:43-57.
- 544 2. Groot H, Munoz-Camargo C, Moscoso J, Riveros G, Salazar V, Florez FK, et al. Skin micro-
545 organs from several frog species secrete a repertoire of powerful antimicrobials in culture. *The*
546 *Journal of antibiotics*. 2012;65(9):461-7.
- 547 3. Kobayashi S, Chikushi A, Tougu S, Imura Y, Nishida M, Yano Y, et al. Membrane
548 translocation mechanism of the antimicrobial peptide buforin 2. *Biochemistry*. 2004;43(49):15610-6.
- 549 4. Muñoz-Camargo C, Montoya VS, Barrero-Guevara LA, Groot H, Boix E, editors. Buforin II
550 bacteria agglutination activity as part of its antimicrobial action mechanism. 2018 IX International
551 Seminar of Biomedical Engineering (SIB); 2018: IEEE.
- 552 5. Muñoz-Camargo C, Salazar VA, Barrero-Guevara L, Camargo S, Mosquera A, Groot H, et al.
553 Unveiling the multifaceted mechanisms of antibacterial activity of buforin II and frenatin 2.3 S
554 peptides from skin micro-organs of the orinoco lime treefrog (*Sphaenorhynchus lacteus*).
555 *International journal of molecular sciences*. 2018;19(8):2170.
- 556 6. Hao G, Shi Y-H, Tang Y-L, Le G-W. The intracellular mechanism of action on *Escherichia*
557 *coli* of BF2-A/C, two analogues of the antimicrobial peptide Buforin 2. *Journal of microbiology*.
558 2013;51(2):200-6.
- 559 7. Park CB, Kim HS, Kim SC. Mechanism of action of the antimicrobial peptide buforin II:
560 buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions.
561 *Biochemical and biophysical research communications*. 1998;244(1):253-7.
- 562 8. Perez C, Radhakrishnan ML, Elmore DE. Investigating Buforin II Interactions with Nucleic
563 Acids under Crowded Conditions. *Biophysical Journal*. 2017;112(3):518a.
- 564 9. Sim S, Wang P, Beyer BN, Cutrona KJ, Radhakrishnan ML, Elmore DE. Investigating the
565 nucleic acid interactions of histone-derived antimicrobial peptides. *FEBS letters*. 2017;591(5):706-
566 17.
- 567 10. Uytendaele ET, Butler CH, Ko D, Elmore DE. Investigating the nucleic acid interactions
568 and antimicrobial mechanism of buforin II. *FEBS letters*. 2008;582(12):1715-8.

- 569 11. Cuellar M, Cifuentes J, Perez J, Suarez-Arnedo A, Serna JA, Groot H, et al. Novel BUF2-
570 magnetite nanobioconjugates with cell-penetrating abilities. *International journal of nanomedicine*.
571 2018;13:8087.
- 572 12. Perez J, Cifuentes J, Cuellar M, Suarez-Arnedo A, Cruz JC, Muñoz-Camargo C. Cell-
573 penetrating and antibacterial BUF-II nanobioconjugates: enhanced potency via immobilization on
574 polyetheramine-modified magnetite nanoparticles. *International journal of nanomedicine*.
575 2019;14:8483.
- 576 13. Jain A, Liu R, Xiang YK, Ha T. Single-molecule pull-down for studying protein interactions.
577 *Nature protocols*. 2012;7(3):445-52.
- 578 14. Daly ML, Gao Y, Freeman R. Encoding reversible hierarchical structures with
579 supramolecular peptide–DNA materials. *Bioconjugate chemistry*. 2019;30(7):1864-9.
- 580 15. Gómez-González J, Pérez Y, Sciortino G, Roldan-Martín L, Martínez-Costas J, Maréchal JD,
581 et al. Dynamic Stereoselection of Peptide Helicates and Their Selective Labeling of DNA Replication
582 Foci in Cells. *Angewandte Chemie*. 2021;133(16):8941-8.
- 583 16. Kokotidou C, Jonnalagadda SVR, Orr AA, Vrentzos G, Kretsovali A, Tamamis P, et al.
584 Designer Amyloid Cell-Penetrating Peptides for Potential Use as Gene Transfer Vehicles.
585 *Biomolecules*. 2020;10(1):7.
- 586 17. Zhang L, Foxman B, Gilsdorf JR, Marrs CF. Bacterial genomic DNA isolation using
587 sonication for microarray analysis. *Biotechniques*. 2005;39(5):640-4.
- 588 18. Li M, Du X, Villaruz AE, Diep BA, Wang D, Song Y, et al. MRSA epidemic linked to a
589 quickly spreading colonization and virulence determinant. *Nature medicine*. 2012;18(5):816-9.
- 590 19. Tello D, Gil J, Loaiza CD, Riascos JJ, Cardozo N, Duitama J. NGSEP3: accurate variant
591 calling across species and sequencing protocols. *Bioinformatics*. 2019;35(22):4716-23.
- 592 20. Johnson M, Zaretskaya I, Raytselis Y, Merezhuk Y, McGinnis S, Madden TL. NCBI BLAST:
593 a better web interface. *Nucleic acids research*. 2008;36(suppl_2):W5-W9.
- 594 21. Tang Y-L, Shi Y-H, Zhao W, Hao G, Le G-W. Interaction of MDpep9, a novel antimicrobial
595 peptide from Chinese traditional edible larvae of housefly, with *Escherichia coli* genomic DNA.
596 *Food chemistry*. 2009;115(3):867-72.
- 597 22. Kong J, Yu S. Fourier transform infrared spectroscopic analysis of protein secondary
598 structures. *Acta biochimica et biophysica Sinica*. 2007;39(8):549-59.
- 599 23. Pillers MA, Shute R, Farchone A, Linder KP, Doerfler R, Gavin C, et al. Preparation of mica
600 and silicon substrates for DNA origami analysis and experimentation. *JoVE (Journal of Visualized*
601 *Experiments)*. 2015(101):e52972.
- 602 24. Miller JH, Ippen K, Scaife JG, Beckwith JR. The promoter-operator region of the lac operon
603 of *Escherichia coli*. *Journal of molecular biology*. 1968;38(3):413-20.
- 604 25. Bailey TL, Johnson J, Grant CE, Noble WS. The MEME suite. *Nucleic acids research*.
605 2015;43(W1):W39-W49.
- 606 26. Song Y, Kang J, Zhou J, Wang Z, Lu X, Wang L, et al. Study on the fluorescence spectra and
607 electrochemical behavior of ZnL2 and Morin with DNA. *Spectrochimica Acta Part A: Molecular and*
608 *Biomolecular Spectroscopy*. 2000;56(12):2491-7.
- 609 27. Carpenter ML, Oliver AW, Geoff Kneale G. Analysis of DNA-protein interactions by
610 intrinsic fluorescence. *DNA-Protein Interactions: Springer*; 2001. p. 491-502.

- 611 28. Sirajuddin M, Ali S, Badshah A. Drug–DNA interactions and their study by UV–Visible,
612 fluorescence spectroscopies and cyclic voltametry. *Journal of Photochemistry and Photobiology B:*
613 *Biology*. 2013;124:1-19.
- 614 29. Zhou Z, Dong S. Protein–DNA interactions: a novel approach to improve the fluorescence
615 stability of DNA/Ag nanoclusters. *Nanoscale*. 2015;7(4):1296-300.
- 616 30. Baguley BC, Le Bret M. Quenching of DNA-ethidium fluorescence by amsacrine and other
617 antitumor agents: a possible electron-transfer effect. *Biochemistry*. 1984;23(5):937-43.
- 618 31. Geall AJ, Blagbrough IS. Rapid and sensitive ethidium bromide fluorescence quenching
619 assay of polyamine conjugate–DNA interactions for the analysis of lipoplex formation in gene
620 therapy. *Journal of pharmaceutical and biomedical analysis*. 2000;22(5):849-59.
- 621 32. Pautler R, Kelly EY, Huang P-JJ, Cao J, Liu B, Liu J. Attaching DNA to nanoceria:
622 regulating oxidase activity and fluorescence quenching. *ACS applied materials & interfaces*.
623 2013;5(15):6820-5.
- 624 33. Saito ST, Silva G, Pungartnik C, Brendel M. Study of DNA–emodin interaction by FTIR and
625 UV–vis spectroscopy. *Journal of Photochemistry and Photobiology B: Biology*. 2012;111:59-63.
- 626 34. Mello MLS, Vidal B. Changes in the infrared microspectroscopic characteristics of DNA
627 caused by cationic elements, different base richness and single-stranded form. 2012.
- 628 35. Tajmir-Riahi H, N'Soukpoe-Kossi C, Joly D. Structural analysis of protein–DNA and
629 protein–RNA interactions by FTIR, UV-visible and CD spectroscopic methods. *Spectroscopy*.
630 2009;23(2):81-101.
- 631 36. de Mello LR, Hamley IW, Castelletto V, Garcia BBM, Han SW, de Oliveira CLP, et al.
632 Nanoscopic structure of complexes formed between DNA and the cell-penetrating peptide penetratin.
633 *The Journal of Physical Chemistry B*. 2019;123(42):8861-71.
- 634 37. Santisteban MS, Kalashnikova T, Smith MM. Histone H2A. Z regulates transcription and is
635 partially redundant with nucleosome remodeling complexes. *Cell*. 2000;103(3):411-22.
- 636 38. Park CB, Yi K-S, Matsuzaki K, Kim MS, Kim SC. Structure–activity analysis of buforin II, a
637 histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating
638 ability of buforin II. *Proceedings of the National Academy of Sciences*. 2000;97(15):8245-50.
- 639 39. Paul C, Wang J, Wimley WC, Hochstrasser RM, Axelsen PH. Vibrational coupling, isotopic
640 editing, and β -sheet structure in a membrane-bound polypeptide. *Journal of the American Chemical*
641 *Society*. 2004;126(18):5843-50.
- 642 40. Piccirilli F, Tardani F, D'Arco A, Birarda G, Vaccari L, Sennato S, et al. Infrared
643 Nanospectroscopy Reveals DNA Structural Modifications upon Immobilization onto Clay
644 Nanotubes. *Nanomaterials*. 2021;11(5):1103.
- 645 41. Pineda JGP, Jimenez JCC, Muñoz-Camargo C, editors. Antimicrobial Activity and
646 Citotoxicity of Buforin II Immobilized on Magnetite Nanoparticles. 2018 AIChE Annual Meeting;
647 2018: AIChE.
- 648 42. Elbel T, Langowski J. The effect of DNA supercoiling on nucleosome structure and stability.
649 *Journal of Physics: Condensed Matter*. 2015;27(6):064105.
- 650 43. Chidchob P, Sleiman HF. Recent advances in DNA nanotechnology. *Current opinion in*
651 *chemical biology*. 2018;46:63-70.



A**B**

Figure 1





Figure 2




A**B****C**

Figure 3




Figure 4






Figure 5



A. Mixing *E. coli* DNA with Buforin II



B. Molecules interaction and conformational changes



C. BUFII-DNA complexation



1. DNA strands conformational change



2. Patern formation along DNA strands




Figure 6